WHO Launches Groundbreaking Online Repository for Evidence-Informed Decision-Making Tools

By Staff Writer

September 19, 2023

Evidence-Informed Decision-Making

The World Health Organization (WHO) has launched an innovative online repository of Evidence-Informed Decision-Making (EIDM) tools. This pioneering platform, the first of its kind, showcases WHO tools and external tools used by WHO to facilitate knowledge translation. It also highlights partner organisations involved in planning, managing, monitoring, and evaluating the process of evidence use and implementation.

Developed by the Evidence to Policy and Impact Unit of the Research for Health Department in the Science Division, in collaboration with the Evidence-Informed Policy Network (EVIPNet), the repository supports the unit’s EIDM capacity-sharing work. The platform complements the WHO evidence ecosystem framework published last year, specifically focusing on the policy/action cycle.

Navigating the Online Platform

The user-friendly online platform enables users to search and access EIDM methods and tools corresponding to each step of the policy/action cycle. Users can refine their searches using advanced functionalities to filter by document type, language, and publication date. The platform offers tools that span the clinical (or practice), public health, and health system domains.

Currently, the repository houses and maintains 75 tools, with continuous updates as new tools emerge. The Evidence to Policy and Impact Unit plans to actively add more tools to the repository, employing a scoping literature review and other steps.

The ultimate goal of EIDM and the work of EVIPNet is to support WHO staff and Member States in applying rigorous, systematic, and transparent methods for the creation and application of research evidence in their day-to-day work. This will enable the organisation to successfully achieve the “Triple Billion” targets: a billion more people with universal health coverage, a billion more people protected from health emergencies, and a billion more people with better health and well-being.

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.